X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer. It is being investigated in combination with MSD’s anti-PD-1 therapy pembrolizumab as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
IMP321 (eftilagimod alpha), a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity. It is being evaluated in phase 2 clinial trials for first line treatment of metastatic non-small cell lung cancer & head & neck squamous cell cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
IMP321 (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with paclitaxel under phase 2/3 clinical trials forthe treatment of patients with metastatic breast carcinoma.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Efti (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with Bavencio (avelumab) under phase 1 clinical trials forthe treatment of patients with metastatic urothelial carcinoma.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
IMP321 (eftilagimod alpha), a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity. It is being evaluated in phase 2 clinial trials for first line treatment of metastatic non-small cell lung cancer & head & neck squamous cell cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer. It is being investigated in combination with MSD’s anti-PD-1 therapy pembrolizumab as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
IMP321 (eftilagimod alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in combination with KEYTRUDA for NSCLC.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase III trial in non-small cell lung cancer.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in combination with KEYTRUDA for soft tissue sarcoma.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in soft tissue sarcoma in neoadjuvant setting.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in soft tissue sarcoma in neoadjuvant setting.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
IMP321 (eftilagimod alpha) binds and activates LAG-3 leading in expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It is being investigated for NSCLC in combination with pembrolizumab.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
IMP321 (eftilagimod alpha) soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. It is being investigated for non-small cell lung cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
IMP321 (eftilagimod alpha) is a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. It is being investigated in combination with bavencio in metastatic urothelial cancer.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in soft tissue sarcoma in neoadjuvant setting.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The agreement aims to expand the INSIGHT-003 trial evaluating the combination of IMP321 (eftilagimod alpha), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1L NSCLC.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is in Phase IIb clinical trial for head and neck squamous cell carcinoma in combination with KEYTRUDA®.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
IMP321 (eftilagimod alpha) binds and activates LAG-3 leading in expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It further boost the immune system’s ability to fight cancer.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
TACTI-003 is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is in Phase IIb clinical trial for head and neck squamous cell carcinoma in combination with KEYTRUDA®.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
IMP321 (eftilagimod alpha), is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator for the treatment of cancer, capitalising on LAG-3’s unique characteristics to stimulate both innate and adaptive immunity.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Efti (IMP321) is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator for the treatment of cancer, capitalising on LAG-3’s unique characteristics to stimulate both innate and adaptive immunity.
Lead Product(s): Eftilagimod Alpha,Oxaliplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
IMP321 (eftilagimod alpha) is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s unique characteristics to stimulate both innate and adaptive immunity.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
The phase I INSIGHT-003 trial is the first trial evaluating Immutep’s lead product candidate, eftilagimod alpha as part of a triple combination therapy consisting of efti and an approved standard of care combination of chemotherapy and an anti-PD-1 therapy.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
IMP321 (Efti) is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator for the treatment of cancer, in particular solid tumors.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Encouraging Phase II data supports broad therapeutic potential of IMP321 (eftilagimod alpha) in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC).
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Collaboration with the Maria Skłodowska-Curie National Research Institute to evaluate efti in triple combination with Keytruda (pembrolizumab) and radiotherapy, followed by surgery.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Maria Skłodowska-Curie National Research Institute
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2022
Details:
Immutep’s intellectual property relating to combined therapeutic preparations comprising (a) its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”), which is a LAG-3 fusion protein (LAG-3Ig), and (b) an anti-PD-(L)1 antibody.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The study is evaluating the combination of Immutep’s IMP321 (eftilagimod alpha) with MSD’s KEYTRUDA® (pembrolizumab) in up to 189 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
The study is evaluating the combination of IMP321 (eftilagimod alpha) with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
IMP321 (eftilagimod alpha), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
TACTI-002 is evaluating combination of Immutep’s eftilagimod alpha, a soluble LAG-3Ig fusion protein and an antigen presenting cell, or APC, activator boosting the immune system with KEYTRUDA in up to 183 patients with second line HNSCC or NSCLC in first and second line.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
The interim data from the TACTI-002 study shows that IMP321 (eftilagimod alpha, efti) in combination with pembrolizumab is demonstrating encouraging early signs of antitumour activity in 2nd line confirmed PD-X refractory, NSCLC patients.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
IMP321 (eftilagimod alpha), is a recombinant protein used in combination with other agents to amplify a patient’s immune response. Efti is a soluble LAG-3Ig fusion protein and an antigen presenting cell, or APC, activator boosting the immune system.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Immutep’s AIPAC trial evaluated its lead product candidate IMP321 (eftilagimod alpha), a soluble LAG-3 fusion protein in combination with paclitaxel chemotherapy in 227 patients with HER2-negative/HR positive metastatic breast cancer.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2022
Details:
Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2022
Details:
Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2022
Details:
Immutep's lead product candidate, Eftilagimod alpha (IMP321), a soluble LAG-3 fusion protein, which is a first-in-class antigen presenting cell activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Carboplatin,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
Eftilagimod alpha soluble LAG-3 fusion protein, which is a first-in-class antigen presenting cell activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
The claims of the new patent protect combined therapeutic preparations comprising MP321 (eftilagimod alpha), which is a soluble LAG-3 fusion protein (LAG-3Ig), and an antiPD-1 or anti-PD-L1 antibody to manufacture of medicament for treatment of cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Undisclosed
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Encouraging Objective Response Rate (ORR) of 29.7% (11/37), including 5 Complete Responses in 2nd line head and neck squamous cell carcinoma (HNSCC) patients in Part C of Phase II TACTI-002 trial.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
The trial evaluated Immutep’s lead product candidate eftilagimod alpha (“efti”) in combination with paclitaxel chemotherapy (efti group, N=114) in comparison to a combination of placebo and paclitaxel chemotherapy (comparator group, N=113).
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
Eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is first-in-class antigen presenting cell activator being explored in cancer and infectious disease. Other regulatory engagement ongoing, including with the US Food and Drug Administration.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Details:
Results from a Phase II study is declared of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC).
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Details:
Efti is exclusively licensed to EOC for the territory of Greater China. EOC has full responsibility for the development and commercialisation of efti in the territory, and Immutep is eligible to receive development-based milestone payments and sales-based royalties.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: EOC202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eoc Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
TACTI-003 will evaluate the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”), in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in approximately 154 patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
Details:
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $82.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 21, 2021
Details:
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Avelumab,Chemotherapy Agent
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
